Suppr超能文献

单克隆IgA抗体在过敏性疾病中的治疗潜力:IgA对致敏小鼠再次接触抗原时由结合相同抗原不同表位的单克隆IgE抗体诱导的免疫反应的抑制作用。

Therapeutic Potential of Monoclonal IgA Antibodies in Allergic Diseases: Suppressive Effect of IgA on Immune Responses Induced By Re-exposure to Antigen in Sensitized Mice by Monoclonal IgE Antibody That Binds to a Different Epitope of the Same Antigen.

作者信息

Yamaki Kouya, Yoshino Shin

机构信息

Department of Pharmacology, Kobe Pharmaceutical University , Kobe, Hyogo, Japan .

出版信息

Monoclon Antib Immunodiagn Immunother. 2015 Apr;34(2):83-9. doi: 10.1089/mab.2014.0078.

Abstract

Repeated exposure to an allergen induces allergic symptoms by activating mast cells that express anti-allergen IgE, which results in further sensitization to an allergen. Considering that additional sensitization elicits more severe allergic reactions upon the next allergen challenge, suppression of the boosting phase represents an efficacious way to prevent and ameliorate allergic diseases. In this study, we investigated the therapeutic potential of allergen-specific monoclonal IgA on allergic diseases. This antibody acts by decreasing immune responses upon exposure to allergens in mice previously sensitized by a monoclonal IgE that recognizes the allergen. The lack of inhibitory effects of anti-ovalbumin monoclonal IgA (OA-4) on either the binding of anti-ovalbumin monoclonal IgE (OE-1) to ovalbumin by ELISA or on ovalbumin-induced degranulation of rat basophilic leukemia RBL2H3 cells sensitized with OE-1 indicated that OA-4 and OE-1 recognized different epitopes on ovalbumin. Immune responses (anti-ovalbumin IgG1 production and cytokine release from splenocytes) induced by intravenous ovalbumin challenge in DBA/1J mice passively sensitized with OE-1 were inhibited by intravenous injection of OA-4 15 min before challenge without affecting anaphylaxis. Moreover, OA-4 injection 1 h after ovalbumin challenge also effectively suppressed immune responses. The achievement of immunosuppression by IgA injection occurred even after allergen challenge in mice in an epitope-independent fashion. These findings suggest that monoclonal IgA administered at the time of hospitalization of a patient with allergic symptoms, who was already exposed to the allergen in the presence of IgE recognizing an undefined epitope(s) on the allergen, should effectively relieve allergic disease through its immunosuppressive effects.

摘要

反复接触过敏原会通过激活表达抗过敏原IgE的肥大细胞来诱发过敏症状,这会导致对过敏原的进一步致敏。鉴于额外的致敏会在下次过敏原激发时引发更严重的过敏反应,抑制增强阶段是预防和改善过敏性疾病的有效方法。在本研究中,我们调查了过敏原特异性单克隆IgA对过敏性疾病的治疗潜力。该抗体通过降低先前被识别该过敏原的单克隆IgE致敏的小鼠接触过敏原后的免疫反应来发挥作用。抗卵清蛋白单克隆IgA(OA-4)对通过ELISA检测的抗卵清蛋白单克隆IgE(OE-1)与卵清蛋白的结合,或对用OE-1致敏的大鼠嗜碱性白血病RBL2H3细胞的卵清蛋白诱导的脱颗粒均无抑制作用,这表明OA-4和OE-1识别卵清蛋白上不同的表位。在用OE-1被动致敏的DBA/1J小鼠中,静脉注射卵清蛋白激发所诱导的免疫反应(抗卵清蛋白IgG1产生和脾细胞释放细胞因子)在激发前15分钟静脉注射OA-4可被抑制,且不影响过敏反应。此外,在卵清蛋白激发后1小时注射OA-4也能有效抑制免疫反应。即使在小鼠接触过敏原激发后,通过注射IgA实现免疫抑制也是以表位非依赖的方式发生的。这些发现表明,在已经在存在识别过敏原上未明确表位的IgE的情况下接触过过敏原的过敏性症状患者住院时给予单克隆IgA,应通过其免疫抑制作用有效缓解过敏性疾病。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验